blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3529241

EP3529241 - PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 [Right-click to bookmark this link]
StatusPatent revoked by proprietor
Status updated on  09.12.2022
Database last updated on 17.07.2024
FormerThe patent has been granted
Status updated on  04.03.2022
FormerGrant of patent is intended
Status updated on  28.10.2021
FormerExamination is in progress
Status updated on  22.10.2020
FormerRequest for examination was made
Status updated on  26.07.2019
FormerThe international publication has been made
Status updated on  28.04.2018
Formerunknown
Status updated on  06.11.2017
Most recent event   Tooltip27.06.2024Lapse of the patent in a contracting state
New state(s): IE		published on 31.07.2024 [2024/31]
Applicant(s)For all designated states
Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon BT63 5QD / GB
[2019/35]
Inventor(s)01 / O'DOWD, Colin
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
02 / HARRISON, Tim
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
03 / HEWITT, Peter
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
04 / ROUNTREE, Shane
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
05 / HUGUES, Miel
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
06 / BURKAMP, Frank
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
07 / JORDAN, Linda
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
08 / HELM, Matthew
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
09 / BROCCATELLI, Fabio
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
10 / CRAWFORD, James John
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
11 / GAZZARD, Lewis
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
12 / WERTZ, Ingrid
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
13 / LEE, Wendy
c/o Almac Discovery Limited
Almac House
20 Seagoe Industrial Estate
Craigavon Armagh BT63 5QD / GB
 [2019/35]
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[2022/14]
Former [2019/35]Boult Wade Tennant LLP
Salisbury Square House
8, Salisbury Square
London EC4Y 8AP / GB
Application number, filing date17790829.020.10.2017
[2019/35]
WO2017GB53175
Priority number, dateGB2016001775820.10.2016         Original published format: GB 201617758
[2019/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018073602
Date:26.04.2018
Language:EN
[2018/17]
Type: A1 Application with search report 
No.:EP3529241
Date:28.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 26.04.2018 takes the place of the publication of the European patent application.
[2019/35]
Type: B1 Patent specification 
No.:EP3529241
Date:06.04.2022
Language:EN
[2022/14]
Search report(s)International search report - published on:EP26.04.2018
ClassificationIPC:C07D401/04, C07D401/06, C07D401/14, C07D403/04, C07D471/04, C07D471/10, C07D473/00, C07D487/04, C07D491/04, C07D513/04, A61K31/506, A61P35/00
[2019/35]
CPC:
C07D471/10 (EP,KR,US); C07D401/06 (EP,KR,US); C07D487/04 (EP,KR,US);
A61K31/506 (EP,KR,US); A61K31/519 (KR); A61K31/522 (KR);
A61K45/06 (KR); A61P35/00 (EP,KR,US); C07D401/04 (EP,KR,US);
C07D401/14 (EP,KR,US); C07D403/04 (EP,KR,US); C07D405/14 (US);
C07D413/14 (US); C07D471/04 (EP,KR,US); C07D473/00 (EP,KR,US);
C07D487/08 (US); C07D491/04 (EP,KR,US); C07D491/107 (US);
C07D493/04 (US); C07D513/04 (EP,KR,US); A61K2300/00 (KR) (-)
C-Set:
A61K31/506, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/35]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PIPERIDINDERIVATE ALS HEMMER DER UBIQUITINSPEZIFISCHEN PROTEASE 7[2019/35]
English:PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7[2019/35]
French:DÉRIVÉS DE PIPÉRIDINE UTILISÉS COMME INHIBITEURS DE LA PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE 7[2019/35]
Entry into regional phase16.05.2019National basic fee paid 
16.05.2019Designation fee(s) paid 
16.05.2019Examination fee paid 
Examination procedure16.05.2019Examination requested  [2019/35]
16.05.2019Date on which the examining division has become responsible
17.12.2019Amendment by applicant (claims and/or description)
21.10.2020Despatch of a communication from the examining division (Time limit: M04)
26.02.2021Reply to a communication from the examining division
23.06.2021Despatch of a communication from the examining division (Time limit: M02)
07.07.2021Reply to a communication from the examining division
29.10.2021Communication of intention to grant the patent
24.02.2022Fee for grant paid
24.02.2022Fee for publishing/printing paid
24.02.2022Receipt of the translation of the claim(s)
Divisional application(s)EP22157226.6  / EP4026832
Revocation procedure29.11.2022Request for revocation under Article 105a
 ADMISSIBLE
14.12.2022Despatch of communication that patent will be revoked
11.01.2023Date of legal effect of revocation of patent
29.11.2022Fee for revocation paid
Former [2023/02]29.11.2022Request for revocation under Article 105a
 ADMISSIBLE
11.01.2023Date of legal effect of revocation of patent
29.11.2022Fee for revocation paid
Former [N/P]29.11.2022Request for revocation under Article 105a
 ADMISSIBLE
Date of legal effect of revocation of patent
29.11.2022Fee for revocation paid
[2023/02]
Fees paidRenewal fee
24.10.2019Renewal fee patent year 03
16.10.2020Renewal fee patent year 04
15.10.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
TR06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
FI20.10.2022
GB20.10.2022
IE20.10.2022
IT20.10.2022
ES21.10.2022
SE21.10.2022
LU31.10.2022
NO31.10.2022
[2024/31]
Former [2024/30]AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
TR06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
FI20.10.2022
GB20.10.2022
IT20.10.2022
ES21.10.2022
SE21.10.2022
LU31.10.2022
NO31.10.2022
Former [2024/29]AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
TR06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
FI20.10.2022
GB20.10.2022
IT20.10.2022
ES21.10.2022
SE21.10.2022
NO31.10.2022
Former [2024/20]AL06.04.2022
AT06.04.2022
CY06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
FI20.10.2022
GB20.10.2022
IT20.10.2022
ES21.10.2022
SE21.10.2022
NO31.10.2022
Former [2024/09]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
GB20.10.2022
IT20.10.2022
ES21.10.2022
SE21.10.2022
NO31.10.2022
Former [2023/49]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
GB20.10.2022
IT20.10.2022
SE21.10.2022
NO31.10.2022
Former [2023/47]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
GB20.10.2022
SE21.10.2022
NO31.10.2022
Former [2023/36]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
SE21.10.2022
NO31.10.2022
Former [2023/35]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
NO31.10.2022
Former [2023/25]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
MC06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SI06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2023/17]AL06.04.2022
AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2023/09]AT06.04.2022
CZ06.04.2022
EE06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
PL06.04.2022
RO06.04.2022
RS06.04.2022
SK06.04.2022
SM06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2022/51]AT06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
PL06.04.2022
RS06.04.2022
BG06.07.2022
GR07.07.2022
IS06.08.2022
PT08.08.2022
Former [2022/50]AT06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
PL06.04.2022
RS06.04.2022
BG06.07.2022
GR07.07.2022
PT08.08.2022
Former [2022/49]AT06.04.2022
HR06.04.2022
LT06.04.2022
LV06.04.2022
BG06.07.2022
GR07.07.2022
PT08.08.2022
Former [2022/47]AT06.04.2022
LT06.04.2022
PT08.08.2022
Cited inInternational search[X]US2011124626  (POONI PARMINDER KAUR [GB], et al) [X] 1,24,25 * Claims 1, 25; examples, e.g. page 54, examples 153, 155. *;
 [X]US2013090341  (KOIKE TATSUKI [JP], et al) [X] 1,24,25 * Claims 1, 13; examples 3, 20, 23-24, 29-30, 33-35, 39-40, 58, 63, 66, 104. *;
 [X]WO2014045101  (CELLZOME GMBH [DE]) [X] 1,24-35 * Claims 1, 25, 29, 33-34; page 29, line 16 to page 33, line 11 (pharmaceutical combinations); page 42, line 6 to page 43, line 10 (e.g. prostate cancer); examples e.g. page 77, example numbers 93-94. *;
 [X]US2014288081  (CIANCHETTA GIOVANNI [US], et al) [X] 1,24-35 * Claims 1-2, 4, 11-12; paragraph [0152]; paragraphs [0154], [0157]; examples, see table 1: inter alia compound numbers 129, 133, 146-148, 153, et cetera, to compound number 434. *;
 [X]US2014371247  (COLLAND FRÉDÉRIC [FR], et al) [X] 1,2,4,24-35 * Abstract; claims; pages 11-12, paragraph 182: examples 1-14. *;
 [X]US2016184318  (BEATTIE DAVID [GB], et al) [X] 1,24-35 * Claims 1, 8-9, 14; paragraph [0648] (prostate cancer); paragraph [0672] (combinations); examples 14-16, 18, 32, 35. *;
 [XI]US2016185785  (IOANNIDIS STEPHANOS [US], et al) [X] 1,3,4,7,8 * Abstract; claims 1, 10, 19-45; examples. * [I] 10-35;
 [XAI]US2016229833  (IOANNIDIS STEPHANOS [US], et al) [X] 1,2,4,18-21,24-35 * Abstract; claims; examples 6, 8; paragraph 73. * [A] 5,6,23 [I] 22;
 [XI]US2016229864  (IOANNIDIS STEPHANOS [US], et al) [X] 1,2,4,24-35 * Abstract; claims; examples. * [I] 3,18-23;
 [XI]US2016229872  (IOANNIDIS STEPHANOS [US], et al) [X] 1,3,4,14,15,24-35 * Abstract; claims; pages 21-22, paragraphs 404-435; examples 14-15. * [I] 2,7,8,10-13,16-23;
 [AP]  - REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20170906), Database accession no. 2125660-51-5, XP002776253 [AP] 1-6,18-35 * abstract *
 [T]  - GAVORY ET AL., "Discovery and characterization of highly potent and selective allosteric USP7 inhibitors", NATURE CHEMICAL BIOLOGY, Basingstoke, (20171204), vol. 14, no. 2, doi:10.1038/nchembio.2528, ISSN 1552-4450, pages 118 - 125, XP055453500 [T] * the whole document *

DOI:   http://dx.doi.org/10.1038/nchembio.2528
ExaminationWO2018020242
by applicantWO9905096
 WO2004058763
 WO2007013964
 EP1749822
 US2008103149
 US2009149466
 WO2010014930
 WO2010081783
 WO2010114881
 WO2011084402
 WO2011086178
 WO2011123419
 WO2013027001
 EP2565186
 WO2013030218
 WO2013134219
 WO2016109515
 WO2016109480
 WO2016126929
 WO2016126926
 WO2016126935
 WO2016150800
 WO2017158381
 WO2017158388
    - HOELLER, Nat. Rev. Cancer, (20060000), vol. 6, pages 776 - 788
    - GAO, Can. J. Physiol. Pharmacol., (20060000), vol. 84, pages 5 - 14
    - LOOSDREGT, Immunity, (20130000), vol. 39, pages 259 - 271
    - RUBINSZTEIN, Nature, (20060000), vol. 443, pages 780 - 786
    - WANG et al., Cell Mol. Immunol., (20060000), vol. 3, pages 255 - 261
    - CORN J. et al., Nat. Struct. Mol. Biol., (20140000), vol. 21, pages 297 - 300
    - NICHOLSON et al., Cell Biochem. Biophys., (20110000), vol. 60, pages 61 - 68
    - KOMANDER, Nat. Rev. Mol. Cell Biol., (20090000), vol. 10, pages 550 - 563
    - CLAGUE, Physiol. Rev., (20130000), vol. 93, pages 1289 - 1315
    - COLLAND, Biochimie, (20080000), vol. 90, pages 270 - 283
    - CUMMINS et al., Cell Cycle, (20040000), vol. 3, pages 689 - 692
    - CUMMINS et al., Nature, (20040000), vol. 428, page 486
    - CHENG et al., Cell Death and Disease, (20130000), vol. 4, page e867
    - REVERDY et al., Chem. Biol., (20120000), vol. 19, pages 467 - 477
    - COLLAND et al., Mol. Cancer Ther., (20090000), vol. 8, pages 2286 - 2295
    - CHAUHAN et al., Cancer Cell, (20120000), vol. 22, pages 345 - 358
    - SONG et al., Nature, (20080000), vol. 455, pages 813 - 817
    - VAN DER HORST et al., Nat. Cell Biol., (20060000), vol. 8, pages 1064 - 1073
    - EPPING et al., Nat. Cell Biol., (20110000), vol. 13, pages 102 - 108
    - MAERTENS et al., EMBO J., (20100000), vol. 29, pages 2553 - 2565
    - FAUSTRUP et al., J. Cell Biol., (20090000), vol. 184, pages 13 - 19
    - DAR et al., Mol Cell Biol., (20130000), vol. 33, pages 3309 - 3320
    - QIN et al., J. Cell Biochem., (20110000), vol. 112, pages 439 - 444
    - DU et al., Sci. Signal., (20100000), vol. 3, page ra80
    - JACKSON et al., Nature Cell Biol., (20140000), vol. 16, pages 1016 - 1026
    - CHENG et al., Oncology Reports, (20130000), vol. 29, pages 1730 - 1736
    - HALL et al., Mol. Endrocrinol., (20140000), vol. 28, pages 912 - 924
    - HOLOWATY et al., J. Biol. Chem., (20030000), vol. 278, pages 29987 - 29994
    - EVERETT et al., J. Virol., (19990000), vol. 73, pages 417 - 426
    - VAN LOOSDREGT et al., Immunity, (20130000), vol. 39, pages 259 - 271
    - J. Org. Chem., (19970000), vol. 62, pages 7512 - 7515
    - J. Med. Chem., (20080000), vol. 51, page 2170
    - J. Am. Chem. Soc., (19570000), vol. 79, page 490
    - J. Combinatorial Chem., (20030000), vol. 5, page 653
    - Org. Biomol. Chem., (20110000), vol. 9, pages 6559 - 6565
    - Tetrahedron Lett., (19980000), vol. 39, page 8593
    - J. Fluorine Chem., (20130000), vol. 152, page 56
    - Org. Process Rev. Dev., (20090000), vol. 13, pages 1161 - 1168
    - Liebigs Annalen der Chemie, (19890000), pages 409 - 411
    - Bioorg. Med. Chem. Lett., (20100000), vol. 20, page 7458
    - Heterocycles, (20090000), vol. 78, page 2477
    - LIN, J. Pharm. Biomed. Anal., (20160000), vol. 122, pages 126 - 140
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.